Clinical Features of Patients Presenting to the Emergency Department With Cardiovascular Adverse Reactions After COVID-19 mRNA Vaccination

Tae Hoon Oh, Seon Hee Woo, Sungyoup Hong, Carol Lee, Woon Jeong Lee, and Si Kyoung Jeong

1Department of Emergency Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea
2Department of Emergency Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea
3Department of Emergency Medicine, David Geffen School of Medicine at UCLA, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA

ABSTRACT

Background: Since the implementation of the nationwide coronavirus disease 2019 (COVID-19) vaccination campaign, emergency departments (EDs) have had an increasing number of patients reporting postvaccination cardiovascular adverse effects. We investigated the clinical features of patients who visited the ED for cardiovascular adverse reactions after COVID-19 mRNA vaccination.

Methods: We conducted a retrospective observational study in two EDs. Patients with cardiovascular adverse reactions after COVID-19 mRNA vaccination who visited EDs between June 1, 2021, and October 15, 2021, were selected. The clinical data of these patients were collected by reviewing medical records.

Results: Among 683 patients, 426 (62.4%) were female. The number of patients in their 20s was the highest (38.9% of males, 28.2% of females) (P < 0.001). More patients visited the ED for adverse reactions following the first vaccine dose than following the second dose (67.6% vs. 32.2%). Chief complaints were chest pain/discomfort (74.4%), dyspnea (14.3%) and palpitation (11.3%). The final diagnosis was a nonspecific cause (63.1%), and 663 (97.1%) patients were discharged from the ED. The admission rate was higher in males than in females (3.9% vs. 1.9%). Myocarditis was diagnosed in four males, who showed mild clinical progression and were discharged within 5 hospital days.

Conclusion: Most patients who visited the ED with cardiovascular adverse reactions were discharged from the ED, but some were admitted for other medical diseases as well as adverse vaccine reactions. Therefore, further surveillance and a differential diagnosis of cardiovascular adverse events after COVID-19 mRNA vaccination should be considered by emergency physicians.

Keywords: COVID-19 mRNA Vaccination; Adverse Reaction; Cardiovascular Symptoms; Emergency Department
INTRODUCTION

After the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, coronavirus disease 2019 (COVID-19) vaccines were developed at an unprecedented rate, and governments have been granting emergency use authority for these vaccines. In South Korea, vaccination was initiated in February 2021, starting with high-risk patients and first-line healthcare workers and gradually expanding to the general public; vaccination for 12th graders was completed in August 2021. Age restrictions were lowered in October, allowing children over the age of 12 years to receive the vaccine.\(^1\)

However, questions regarding the safety of these COVID-19 vaccines due to a lack of clinical trials have been raised continuously. Several studies have reported rare but severe adverse reactions to COVID-19 mRNA vaccines.\(^2,3\) Some studies have reported the possibility of a causal relationship between COVID-19 mRNA vaccination and the risk of myocarditis/pericarditis in adolescent and young adult males.\(^4-6\) In clinical practice, as COVID-19 mRNA vaccination was expanded to the general population, the number of patients presenting to the ED with cardiovascular symptoms increased. Using mobile self-report questionnaires, a survey studies on adverse reactions following administration of the ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine in healthcare workers found that females and younger age groups reported adverse reactions more frequently than males and older age groups.\(^7,8\) As such, there may be differences in adverse reactions by sex and age group.

Unlike general adverse reactions, such as fever, chills, myalgia, fatigue, and headache, cardiovascular symptoms require more attention from emergency physicians and more in-depth evaluation for a differential diagnosis considering other serious diseases, as these symptoms could be red flags for potentially life-threatening conditions. This has led to a substantial burden on first-line health care workers in the ED who are already occupied with COVID-19 screening tasks.

Therefore, we investigated the clinical characteristics of patients presenting to the ED with cardiovascular adverse reactions after COVID-19 mRNA vaccination and analyzed differences in clinical features according to sex and age group.

METHODS

Study design and data collection

The ‘Infectious Disease Control and Prevention Act’ of South Korea requires medical staff to report any suspected COVID-19 vaccine-related adverse events. In compliance with this Act, we have been reporting adverse events to the COVID-19 Immunization Registry System (IRS) since March 2021.

We conducted a retrospective observational study in two hospitals, Incheon and Daejeon, whose EDs serve as regional emergency centers in South Korea. Among the patients who visited the EDs of the two hospitals between June 1, 2021, and October 15, 2021, patients with adverse reactions reported to the COVID-19 IRS were selected. The subjects for this study were included based on cardiovascular adverse reactions after COVID-19 mRNA vaccination and were 65 years or younger. The exclusion criteria were as follows: received of a viral vector COVID-19 vaccine, presented with noncardiovascular symptoms, aged more than 65 years,
and with incomplete data. The types of COVID-19 mRNA vaccines included Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273). Chest pain/discomfort, dyspnea and palpitation were considered cardiovascular symptoms. Onset day was set to 0 days, if cardiovascular symptoms occurred on the day of vaccination.

We collected data on patient sex, age, type of vaccine administered, vaccine dose (first or second), chief complaints, vital signs upon admission, laboratory data, outcomes (discharge or admission), ED length of stay, intravenous hydration and parenteral medication prescribed during ED stay, and final diagnosis.

**Statistical analysis**

Data were analyzed as absolute frequencies, percentages, mean averages, and standard deviations. Age groups were divided into one of the following: 17 to 19 years, 20 to 29 years, 30 to 39 years, 40 to 49 years, 50 to 59 years, and 60 to 65 years.

We compared the mean of continuous variables using student’s *t*-test and compared the distribution of dichotomous variables using the chi-square test with Yates correction for continuity or Fisher’s exact test between male and female groups. A *P* value of 0.05 or less was considered a statistically significant difference. All statistical analyses were analyzed using R statistics version 4.1.1 (R foundation for statistical computing, Vienna, Austria).

**Ethics statement**

Institutional Review Board of Daejeon St. Mary’s Hospital and Incheon St. Mary’s Hospital approved this study (approval No. DC21RIDI0073 by Daejeon and OC21RIDI0122 by Incheon). Informed consent was waived because of the retrospective nature of this study.

**RESULTS**

**Patient characteristics**

Two thousand forty-one cases of COVID-19 vaccine adverse reactions were reported to the IRS from EDs during the study period. A total of 1,397 patients visited the ED after experiencing adverse COVID-19 mRNA vaccine reactions, and 683 were included in this study (Fig. 1). A total of 426 (62.4%) were female, and the largest proportion of patients was in their 20s (Fig. 2). Both males and females visited the ED more frequently after the first vaccine dose than after the second dose, except for the 17–19 age group (Fig. 3).

The mean age of males was younger than that of females (32.7 ± 12.1 vs. 37 ± 12.5, *P* < 0.001) (Table 1). Males presented with more chest pain/discomfort than females (81.7% vs. 70%, *P* = 0.003), while females presented with more dyspnea and palpitation than males. A total of 663 (97.1%) patients were discharged from the ED, and 18 (2.9%) were admitted to the hospital. Although the admission rate was higher in males than in females, there was no significant difference (3.9% vs. 1.9%).

Cardiac enzyme and NT-proBNP levels were within normal limits for most patients (Table 2). Among 676 patients who underwent an electrocardiogram (EKG) test, 8 (1.2%) had ST-segment changes, and males had more ST-segment changes than females (1.9% vs. 0.7%, *P* < 0.001). Other EKG abnormalities included sinus tachycardia 25 (3.7%), premature ventricular contractions 13 (1.9%), and right bundle branch block 11 (1.6%). During the ED stay, narcotic
analgesics were administered more frequently in females than in males (8.2% vs. 2.7%, \(P = 0.006\)). The final diagnosis was in the order of nonspecific causes, mental disorders (including hyperventilation, anxiety, and panic disorder), angina and gastroesophageal reflux disease (GERD). Fig. 4 shows that most patients reported cardiovascular-adverse reactions within 7 days after vaccination, after both the first and second doses (81.9% and 86.4%).

**Clinical features of inpatients**

Among the 683 patients, 10 (3.9%) males and 8 (1.9%) females were admitted to the hospital. One male patient diagnosed with myocarditis was discharged against medical advice (DAMA). Table 3 shows the detailed clinical features of the inpatients. Myocarditis was diagnosed in four male patients. They were 17, 17, 24 and 49 years old, respectively; had no...
comorbidities; showed cardiac enzyme elevation but no abnormalities on echocardiography; and mild clinical progression. Three inpatients with myocarditis were discharged within 5 hospital days without any complications. And the one DAMA patient also showed improved symptoms, normalized cardiac enzyme levels, and a decreased amount of pleural effusion at the outpatient follow-up visit 2 days later. Cardiac diseases were diagnosed in 6 males

Fig. 3. Distribution of patients after the first and second vaccine dose. A total of 70.8% of males and 65.7% of females visited the ED following the first vaccine dose. (A) In males, the number of visits was larger after the first dose than after the second dose in all age groups, except for the 17–19 age group. Males in their 20s visited the ED four time more frequently after the first than after the second (P < 0.001). (B) Females also visited the ED more often after the first dose, except for those in the 17–19 and 60–65 age groups (P = 0.110). ED = emergency department.

Table 1. Patient characteristics

| Variables                  | Total, N = 683 (100%) | Male, n = 257 (37.6%) | Female, n = 426 (62.4%) | Ratio (M : F) | P value |
|----------------------------|------------------------|------------------------|--------------------------|---------------|---------|
| Age, mean, yr              | 35.4 ± 12.5            | 32.7 ± 12.1            | 37 ± 12.5                |               | < 0.001 |
| Vaccine type               |                        |                        |                          |               | 0.397   |
| Pfizer-BionTech            | 577 (84.4)             | 221 (85.9)             | 356 (83.5)               | 1.02          |         |
| Moderna                    | 106 (15.6)             | 36 (14.1)              | 70 (16.5)                | 0.8           |         |
| V/S on admission           |                        |                        |                          |               |         |
| Systolic blood pressure    | 136.4 ± 18.6           | 137.9 ± 17.6           | 135.4 ± 19.1             |               | 0.075   |
| Diastolic blood pressure   | 86.9 ± 44.7            | 89.8 ± 70.6            | 85.1 ± 13.9              |               | 0.295   |
| Heart rate                 | 90.8 ± 16.4            | 89.5 ± 16.4            | 91.6 ± 16.4              |               | 0.104   |
| Respiratory rate           | 20.2 ± 7.8             | 19.9 ± 1.7             | 20.4 ± 9.8               |               | 0.316   |
| Body temperature           | 36.8 ± 0.55            | 36.7 ± 0.5             | 36.8 ± 0.53              |               | 0.325   |
| Chief complaints           |                        |                        |                          |               | 0.003   |
| Chest pain/discomfort      | 508 (74.4)             | 210 (81.7)             | 298 (70.0)               | 1.16          |         |
| Dyspnea                    | 98 (14.3)              | 28 (10.9)              | 70 (16.4)                | 0.66          |         |
| Palpitation                | 77 (11.3)              | 19 (7.4)               | 58 (13.6)                | 0.54          |         |
| Underlying disease         |                        |                        |                          |               |         |
| Hypertension               | 46 (6.7)               | 18 (2.6)               | 26 (3.8)                 | 0.68          | 0.761   |
| Diabetes mellitus          | 21 (3.1)               | 12 (1.8)               | 9 (1.3)                  | 1.38          | 0.099   |
| Mental disorders           | 18 (2.6)               | 4 (1.6)                | 14 (3.3)                 | 0.48          | 0.262   |
| Thyroid disease            | 15 (2.2)               | 2 (0.8)                | 13 (3.1)                 | 0.26          | 0.090   |
| GERD                       | 14 (2.0)               | 4 (1.6)                | 10 (2.3)                 | 0.69          | 0.669   |
| Allergic rhinitis          | 13 (1.9)               | 6 (2.3)                | 7 (1.6)                  | 1.4           | 0.569   |
| Asthma                     | 11 (1.6)               | 4 (1.6)                | 7 (1.6)                  | 1             | 1.000   |
| Arrhythmia                 | 10 (1.5)               | 4 (1.6)                | 6 (1.4)                  | 1.1           | 1.000   |
| Coronary artery disease    | 9 (1.3)                | 6 (2.3)                | 3 (0.7)                  | 3.28          | 0.087   |
| Discharge outcomes         |                        |                        |                          |               | 0.179   |
| Discharge                  | 663 (97.1)             | 247 (96.1)             | 418 (98.1)               | 0.97          |         |
| Admission                  | 18 (2.9)               | 10 (3.9)               | 8 (1.9)                  | 2.05          |         |

Values are presented as mean ± standard deviation or number (%).
GERD = gastroesophageal reflux disease.
(3 myocarditis, 1 angina, 1 ST-elevation myocardial infarction [STEMI], 1 non-STEMI [NSTEMI]) and 2 females (2 heart failure).

**DISCUSSION**

Large-scale public COVID-19 vaccination campaigns have led to an increasing number of patients presenting to the ED with vaccine-related adverse reactions. In a mobile-based study conducted in South Korea, the most common adverse reactions following BNT162b2 mRNA vaccinations (Pfizer-BioNTech) were muscle aches (69.1%), fatigue (65.7%), headache (48.7%), chills (44.2%), and fever (32.1%), while 13.5% reported chest discomfort and palpitation. The Korea Disease Control and Prevention Agency reported that cardiovascular symptoms accounted for 13.6% of all reported COVID-19 mRNA-related adverse reactions. However, in this study, 712 (51%) out of 1,397 patients who visited the ED after receiving the COVID-19 mRNA vaccine reported cardiovascular symptoms as adverse reactions. This higher rate is thought to be because this study was conducted in an ED population.

Myocarditis has been recognized as a rare complication of COVID-19 mRNA vaccination and usually occurs 2 to 3 days after receiving the second vaccine dose. The highest incidence was among young adult and adolescent males, and most cases of myocarditis were mild or moderate in severity. In this study, four males were diagnosed with myocarditis. They were 17, 17, 24 and 49 years old, respectively; had elevated cardiac enzyme levels, nonspecific...
EKG findings (except for the 24-year-old patient) and no abnormalities on echocardiography; two out of the four patients developed symptoms after the second dose; and symptom onset was 0, 1, 3, and 23 days after vaccination, respectively. One study investigated adverse reactions until 21 and 30 days following the first and second doses, respectively. Another study analyzed adverse reactions up to 42 days after the first dose. In this study, the patient who developed symptoms on the 23rd day after vaccination had ST elevation on his EKG, even though normal echocardiographic findings were observed. He underwent coronary angiography, which confirmed normal findings. In this patient with late onset, COVID-19 vaccination could not be excluded as a cause of myocarditis. All four cases of myocarditis had mild clinical progression, so cardiac magnetic resonance imaging (MRI) was not needed to confirm myocarditis. Myocarditis must be considered, especially in young adults and adolescents presenting to the ED with cardiovascular symptoms following COVID-19 mRNA vaccination, and invasive coronary angiography must be carefully considered.

Myocarditis/pericarditis is a rare disease commonly caused by viral infection, including SARS-CoV-2 infection. The exact incidence rate of myocarditis is unknown due to difficulty in diagnosis. Endomyocardial biopsy (EMB) is the gold standard for a definitive diagnosis of myocarditis but is rarely performed due to the high-risk nature of the procedure. Recent advancements in cardiac MRI technology are associated with the increased annual incidence

---

**Fig. 4.** Onset days since vaccination by sex. Most patients reported cardiovascular symptoms during the first few days after vaccination. (A) After the first vaccine dose, 68.1% of males and 61.8% of females reported symptoms within 3 days. The latest onset days were 23 and 33 days in males and females, respectively. (B) After the second dose, 77.3% of males and 74.0% of females reported adverse reactions within 3 days. The latest onset days were 30 and 38 days in males and females, respectively.
of myocarditis.\textsuperscript{15,16} The Center for Disease Control and Prevention (CDC) established a myocarditis case definition by adding cardiac MRI findings to Sagar's classification system.\textsuperscript{17} Following the CDC definition, four cases of myocarditis in this study were classified as probable myocarditis, as the patients did not undergo EMB or cardiac MRI.

The final diagnoses included mental disorders (panic disorder, anxiety, or hyperventilation), GERD, costochondritis, and gastritis. These diseases can manifest as symptoms similar to cardiovascular symptoms, so a differential diagnosis is required. Additionally, two admitted males who visited the ED for vaccine adverse reactions were ultimately diagnosed with myocardial infarction. This suggests that emergency physicians must consider medical diseases other than adverse vaccine reactions.

In this study, prescriptions for nitroglycerine and analgesics were low. Considering that there were many nonspecific causes in the final diagnosis, it is thought that most patients had pain/discomfort that did not require pain control, although this is a limited interpretation of retrospective studies. In females, more narcotic medications were administered for pain relief than nonsteroidal anti-inflammatory drugs. This requires further research, utilizing a tool such as a pain score, in the future.

### Table 3. Clinical characteristics of inpatients

| No. | Sex | Age | Diagnosis                        | Underlying disease | Vaccine dose | Onset days | Chief complaints     | CK-MB | Trop-T | NT-proBNP | EKG       | Echo | CAG | In-ICU | In-hospital |
|-----|-----|-----|----------------------------------|--------------------|--------------|------------|----------------------|-------|--------|-----------|-----------|------|-----|--------|-------------|
| 1   | M   | 17  | Myocarditis                      | No                 | 2nd          | 3          | Chest pain           | 25.11 | 488    | 69.5      | N-S       | N-S  | NA  | HD 3   |             |
| 2   | M   | 17  | Myocarditis                      | No                 | 2nd          | 1          | Chest pain           | 23.95 | 239    | 282       | N-S       | N-S  | NA  | HD 3   |             |
| 3   | M   | 18  | Pneumothorax                     | No                 | 2nd          | 1          | Chest pain           | 0.94  | 5.12   | 17.1      | N-S       | N-S  | NA  | HD 3   |             |
| 4   | M   | 18  | Atypical chest pain              | Allergic rhinitis  | 2nd          | 1          | Chest pain           | 0.46  | 3.61   | 7.18      | N-S       | N-S  | NA  | HD 3   |             |
| 5   | M   | 18  | Angina                           | No                 | 2nd          | 2          | Chest pain           | 1.01  | 6.3    | 43.8      | N-S       | N-S  | NA  | HD 3   |             |
| 6   | M   | 24  | Myocarditis                      | No                 | 1st          | 23         | Chest pain           | 74.81 | 2,503  | NA        | ST elevation | N-S  | N-S | HD 3   | HD 5        |
| 7   | M   | 46  | STEMI                            | No                 | 1st          | 1          | Chest pain           | 1.27  | 21.3   | NA        | ST elevation | N-S  | PCI on LAD, RCA | HD 2   | HD 4        |
| 8   | M   | 49  | Pneumonia                        | No                 | 1st          | 9          | Dyspnea              | 2.19  | 4      | NA        | N-S       | NA   | NA  | HD 6   |             |
| 9   | M   | 54  | DLBCL                            | Liver cirrhosis    | 1st          | 0          | Dyspnea              | 0.73  | 7      | 313       | N-S       | NA   | NA  | HD 8   |             |
| 10  | M   | 58  | NSTE MI                          | Hypertension       | 2nd          | 26         | Chest pain           | 1.93  | 21.2   | 74.1      | ST elevation | N-S  | NA  | HD 6   | HD 6        |
| 11  | F   | 34  | Ischemic colitis                 | No                 | 1st          | 18         | Chest pain           | 0.28  | 3.71   | 117       | N-S       | NA   | NA  | HD 6   |             |
| 12  | F   | 35  | Hepatitis                        | No                 | 2nd          | 4          | Chest pain           | 0.95  | 4.7    | 73.4      | N-S       | NA   | NA  | HD 4   |             |
| 13  | F   | 38  | Cholecystitis                    | No                 | 2nd          | 0          | Chest pain           | 0.45  | 3.37   | NA        | N-S       | NA   | NA  | HD 4   |             |
| 14  | F   | 39  | HF                               | Pericardial effusion | 1st          | 3          | Chest pain           | 2.31  | 14.2   | 2,165     | Poor R  | Global hypokinesia | NA   | HD 9   |
| 15  | F   | 41  | Costochondritis                  | Adenomyosis        | 1st          | 0          | Chest pain           | 0.83  | 3      | 63.8      | N-S       | N-S  | N-S | HD 2   |             |
| 16  | F   | 53  | HF                               | Breast cancer       | 1st          | 2          | Dyspnea              | 2.28  | 18.4   | 5,529     | AF        | Global dysfunction | NA   | HD 3   | HD 12  |
| 17  | F   | 55  | Hepatitis                        | No                 | 1st          | 0          | Chest pain           | 0.75  | 4.1    | 139       | ST depression | NA   | NA  | HD 3   |             |
| 18  | F   | 64  | Pneumonia                        | No                 | 2nd          | 1          | Dyspnea              | 1.44  | 3      | 72.5      | N-S       | NA   | NA  | HD 8   |             |
| *   | M   | 49  | Myocarditis HF, pericardial effusion | No                 | 1st          | 0          | Chest pain           | 1.77  | 128    | 1,200     | VPC       | N-S  | NA  | DAMA   |             |

Abnormal findings on blood tests are marked in bold. Data from one DAMA patient with myocarditis are indicated as *. EKG = electrocardiogram, CAG = cardiac angiography, ICU = intensive care unit, N-S = non-specific, NA = not available, HD = hospital day, STEMI = ST segment elevation myocardial Infarction, LAD = left anterior descending, RCA = right coronary artery, PCI = percutaneous coronary intervention, DLBCL = diffuse large B-cell lymphoma, NSTE MI = non-ST segment elevation myocardial infarction, HF = heart failure, AF = atrial flutter, VPC = ventricular premature contraction, DAMA = discharge against medical advice.
The 17–19 age group displayed different characteristics compared to the other age groups. They showed that there were more males than females, visited the ED more frequently after the second dose than after first dose, and higher diagnostic rates of myocarditis. These results were similar to those of other studies of myocarditis after COVID-19 mRNA vaccination.\textsuperscript{3,10,11}

There were more females than males in this study, similar to other studies on vaccine adverse reactions.\textsuperscript{7,8} One study reported that female sex was the main covariable, although a clear explanation of such an observation has not been provided.\textsuperscript{18}

Limitations in this study are its retrospective nature and small sample size. This study was performed in two hospitals; therefore, selection bias might have occurred. In addition, only patients between 17–19 years old were included in this study due to government age restrictions for vaccination; therefore, the results do not represent all teenagers. The results of vaccine types should be interpreted with caution, as the vaccination rates and administered vaccine types were different for each age group during this study period.

There are no studies on patients presenting to the ED with cardiovascular adverse reactions after COVID-19 vaccination. Therefore, this study can provide a guide for decision-making and patient disposition within the ED. In addition, this study can serve as a valuable reference for the comparison of adolescents and adults, following the South Korean government’s decision to expand vaccinations to those 12 years of age or older.

In conclusion, the majority of patients with cardiovascular adverse reactions after COVID-19 mRNA vaccination were female, and visited the ED more frequently after the first vaccine dose. The number of patients in their 20s was the highest; most of patients were discharged from the ED; the admission rate was higher in males; and all four cases of myocarditis were diagnosed in males and showed mild clinical progression.

ACKNOWLEDGMENTS

We thank all healthcare workers, especially our colleagues of the emergency department of Daejeon St. Mary’s Hospital and Incheon St. Mary’s Hospital, for their dedication to combating the COVID-19 pandemic.

REFERENCES

1. Korea Disease Control and Prevention Agency. Criteria for Covid-19 vaccination (revised 211001). https://ncv.kdca.go.kr/board.es?mid=a12101000000&bid=0031. Updated 2021. Accessed October 5, 2021.
2. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. \textit{N Engl J Med} 2020;383(27):2603-15. \texttt{PUBMED} | \texttt{CROSSREF}
3. Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. \textit{N Engl J Med} 2021;385(23):2140-9. \texttt{PUBMED} | \texttt{CROSSREF}
4. Centers for Disease Control and Prevention. Advisory committee on immunization practices (ACIP), COVID-19 vaccine safety updates, June 23, 2021. http://cdc.gov/coronavirus. Updated 2021. Accessed July 6, 2021.
5. Kime P. Pentagon tracking 14 cases of heart inflammation in troops after COVID19 shots. 2021. https://www.military.com/daily-news/2021/04/26/pentagon-tracking-14-cases-of-heart-inflammation-troops-after-covid-19-shots.html. Updated 2021. Accessed May 16, 2021.

6. Reuters. Israel examining heart inflammation cases in people who received Pfizer COVID shot. https://www.reuters.com/world/middle-east/israel-examining-heart-inflammation-cases-people-who-received-pfizer-covid-shot-2021-04-25/. Updated April 25, 2021.

7. Rae S, Lee YW, Lim SY, Lee JH, Lim JS, Lee S, et al. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci 2021;36(17):e115. PUBMED | CROSSREF

8. Lee YW, Lim SY, Lee JH, Lim JS, Kim M, Kwon S, et al. Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. J Korean Med Sci 2021;36(21):e153. PUBMED | CROSSREF

9. Korea Disease Control and Prevention Agency. Weekly COVID-19 vaccination adverse event (Week 33). https://ncv.kdca.go.kr/board.es?mid=a11707010000&bid=0032#content. Updated 2021. Accessed October 21, 2021.

10. Bozkurt B, Kamat I, Hotze PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation 2021;144(6):471-84. PUBMED | CROSSREF

11. Witberg G, Bara N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med 2021;385(23):2132-9. PUBMED | CROSSREF

12. Kim J, Cho MJ. Acute myocarditis in children: a 10-year nationwide study (2007–2016) based on the Health Insurance Review and Assessment Service Database in Korea. Korean Circ J 2020;50(11):1013-22. PUBMED | CROSSREF

13. Arola A, Pikkarainen E, Sipilä JO, Pykäri J, Rautava P, Kyrö V. Occurrence and features of childhood myocarditis: a nationwide study in Finland. J Am Heart Assoc 2017;6(11):e005306. PUBMED | CROSSREF

14. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Birlyukov S, Bolliger I, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386(9995):743-800. PUBMED | CROSSREF

15. Park H, Yun KW, Kim KR, Song SH, Ahn B, Kim DR, et al. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of mRNA COVID-19 vaccine in Korean children: a multicenter study. J Korean Med Sci 2021;36(32):e232. PUBMED | CROSSREF

16. Olejniczak M, Schwartz M, Webber E, Shaffer A, Perry TE. Viral myocarditis-incidence, diagnosis and management. J Cardiothorac Vasc Anesth 2020;34(6):1591-601. PUBMED | CROSSREF

17. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). Coronavirus disease 2019 (COVID-19) vaccines. https://www.cdc.gov/vaccines/acip/meetings/slides-2021-06.html. Updated 2021. Accessed July 6, 2021.

18. Govaert TM, Dinant GI, Aretz K, Masurel N, Sprenger MJ, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 1993;307(6910):988-90. PUBMED | CROSSREF